Cargando…

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease

Substrate reduction therapy (SRT) in clinic adequately manages the visceral manifestations in Gaucher disease (GD) but has no direct effect on brain disease. To understand the molecular basis of SRT in GD treatment, we evaluated the efficacy and underlying mechanism of SRT in an immortalized neurona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Yanyan, Liou, Benjamin, Lin, Yi, Fannin, Venette, Zhang, Wujuan, Feldman, Ricardo A., Setchell, Kenneth D. R., Grabowski, Gregory A., Sun, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466461/ https://www.ncbi.nlm.nih.gov/pubmed/34571934 http://dx.doi.org/10.3390/cells10092286

Ejemplares similares

Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease
por: Sun, Ying, et al.
Publicado: (2013)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
por: Sun, Ying, et al.
Publicado: (2020)

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease
por: Dai, Mei, et al.
Publicado: (2016)

Combination of acid β-glucosidase mutation and Saposin C deficiency in mice reveals Gba1 mutation dependent and tissue-specific disease phenotype
por: Liou, Benjamin, et al.
Publicado: (2019)

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases
por: Zhao, Xiangli, et al.
Publicado: (2022)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014)

Global gene expression profile progression in Gaucher disease mouse models
por: Xu, You-Hai, et al.
Publicado: (2011)

mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells
por: Brown, Robert A., et al.
Publicado: (2019)

Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology
por: Sun, Ying, et al.
Publicado: (2015)

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies
por: Wagner, Victoria F., et al.
Publicado: (2017)

mTOR Pathways in Cancer and Autophagy
por: Paquette, Mathieu, et al.
Publicado: (2018)

Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

The mTOR–Autophagy Axis and the Control of Metabolism
por: Deleyto-Seldas, Nerea, et al.
Publicado: (2021)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Autophagy termination and lysosome reformation regulated by mTOR
por: Yu, Li, et al.
Publicado: (2010)

mTOR's role in ageing: protein synthesis or autophagy?
por: Hands, Sarah L., et al.
Publicado: (2009)

mTOR, AMBRA1, and autophagy: An intricate relationship
por: Nazio, Francesca, et al.
Publicado: (2013)

Reversing autism by targeting downstream mTOR signaling
por: Wang, Hansen, et al.
Publicado: (2013)

Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat
por: Harai, Nozomi, et al.
Publicado: (2023)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis
por: Gui, Yao-Song, et al.
Publicado: (2015)

Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
por: Zhu, Zhou, et al.
Publicado: (2019)

Pleiotropic Effects of mTOR and Autophagy During Development and Aging
por: Schmeisser, Kathrin, et al.
Publicado: (2019)

The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases
por: Wang, Haojie, et al.
Publicado: (2019)

mTORC2: The other mTOR in autophagy regulation
por: Ballesteros‐Álvarez, Josué, et al.
Publicado: (2021)

Celastrol promotes chondrocyte autophagy by regulating mTOR expression
por: Dai, Siming, et al.
Publicado: (2022)

Role of mTOR through Autophagy in Esophageal Cancer Stemness
por: Du, Liang, et al.
Publicado: (2022)

Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency
por: Zhao, Xueheng, et al.
Publicado: (2022)

Phosphorylation of the novel mTOR substrate Unkempt regulates cellular morphogenesis
por: Baskaran, Pranetha, et al.
Publicado: (2022)

Exploring mTOR inhibition as treatment for mitochondrial disease
por: Sage‐Schwaede, Abigail, et al.
Publicado: (2019)

Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013)

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
por: Walters, Hannah E., et al.
Publicado: (2016)

Berberine Reverses Doxorubicin Resistance by Inhibiting Autophagy Through the PTEN/Akt/mTOR Signaling Pathway in Breast Cancer
por: Wang, Ye, et al.
Publicado: (2020)

Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy
por: Boddupalli, Chandra Sekhar, et al.
Publicado: (2022)

mTOR-Controlled Autophagy Requires Intracellular Ca(2+) Signaling
por: Decuypere, Jean-Paul, et al.
Publicado: (2013)

Regulation of Autophagy in Chick Skeletal Muscle: Effect of mTOR Inhibition
por: Nakashima, Kazuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6mrssn8gprjjf0fv2g8hkg4bh3